Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

 
• By Cathy Kelly

Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.

Disruptive innovation Independent leadership concept and individuality as a group of acrobatic jets with one individual jet going in the opposite direction as a business symbol for new thinking. - Illustration
Amgen Charting Its Own Course On Biosimilar Policy

More from Biosimilars

More from Biosimilars & Generics